ACRV
Acrivon Therapeutics·NASDAQ
--
--(--)
--
--(--)
ACRV fundamentals
Acrivon Therapeutics (ACRV) released its earnings on Nov 13, 2025: revenue was 0 (YoY --), met estimates; EPS was -0.47 (YoY +20.34%), beat estimates.
Revenue / YoY
0
--
EPS / YoY
-0.47
+20.34%
Report date
Nov 13, 2025
EPS
Actual | -0.8 | -0.58 | -0.63 | -0.66 | -0.86 | -0.73 | -0.52 | -0.59 | -0.6 | -0.51 | -0.55 | -0.47 |
Forecast | -0.81 | -0.6505 | -0.648 | -0.7083 | -0.728 | -0.8398 | -0.6026 | -0.5784 | -0.6636 | -0.6425 | -0.5678 | -0.5911 |
Surprise | +1.23% | +10.84% | +2.78% | +6.82% | -18.13% | +13.07% | +13.71% | -2.01% | +9.58% | +20.62% | +3.13% | +20.49% |
Revenue
Actual | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Forecast | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Earnings Call
You can ask Aime
What is the market's earnings forecast for Acrivon Therapeutics next quarter?What were the key takeaways from Acrivon Therapeutics's earnings call?What were the key takeaways from Acrivon Therapeutics’s earnings call?What does Acrivon Therapeutics do and what are its main business segments?What is Acrivon Therapeutics's latest dividend and current dividend yield?What guidance did Acrivon Therapeutics's management provide for the next earnings period?Did Acrivon Therapeutics beat or miss consensus estimates last quarter?What is Acrivon Therapeutics's gross profit margin?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
